Product Information

TROKENDI XR 50 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $17.4332 per EA under NDC 17772010230. Its NADAC has been published 459 times since Nov 8, 2017.

FDA first approved this application on Aug 16, 2013. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TROKENDI XR 50 MG CAPSULE

topiramate
$17.4332per EA

Strength

50 mg/1

NDC

17772010230

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

7/1/2026

Active Ingredients

TOPIRAMATE

Approval Type

New Drug (NDA)

FDA Application

NDA201635

FDA Approved

8/16/2013

TE Code

AB1

On Market Since

8/16/2013

Pharmacological Classes

Cytochrome P450 2C19 Inhibitors
Cytochrome P450 3A4 Inducers
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for TROKENDI XR 50 MG CAPSULE has been published 459 times since Nov 8, 2017, and over the history we have for it it has risen 69.6%. The table below summarizes its recorded NADAC range and movement.

Current price$17.4332 per EA
All-time high$17.4332 (Aug 19, 2026)
All-time low$10.2278 (Dec 20, 2017)
52-week high$17.4332
52-week low$15.2795
Median price$14.4845
Average price$13.9048
Largest weekly change+8.0% (Jul 8, 2026)
Weeks tracked459
Tracking sinceNov 8, 2017

Price History

1W

0.0%

1M

0.0%

3M

+7.2%

6M

+7.6%

1Y

+14.1%

3Y

+13.5%

5Y

+27.7%

All

+69.6%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 81% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of TROKENDI XR 50 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for TROKENDI XR 50 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $17.4332 per EA (NDC 17772010230), effective Aug 19, 2026.

How has the price of TROKENDI XR 50 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for TROKENDI XR 50 MG CAPSULE has risen 69.6%. It has been tracked across 459 weekly CMS publications since Nov 8, 2017.

What are the highest and lowest recorded NADAC prices for TROKENDI XR 50 MG CAPSULE?

Since Nov 8, 2017, the NADAC for TROKENDI XR 50 MG CAPSULE has ranged from a low of $10.2278 (Dec 20, 2017) to a high of $17.4332 (Aug 19, 2026), with a median of $14.4845 per EA.

Are there cheaper alternatives to TROKENDI XR 50 MG CAPSULE?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 50 MG SPRINKL CAP, is $3.3778 per EA — about 81% below TROKENDI XR 50 MG CAPSULE.

Who manufactures TROKENDI XR 50 MG CAPSULE?

TROKENDI XR 50 MG CAPSULE (NDC 17772010230) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.